A study evaluating 4 PD-L1 assay tests has found that one reveals statistically lower levels of programmed death ligand 1 (PD-L1) expression than the others, which could influence provider and patient decision-making.
Hypofractionated radiation therapy is less toxic and just as effective as conventional radiation therapy in patients with non-small cell lung cancer (NSCLC), according to research presented at the 58th Annual Meeting of the American Society for Radiation Oncology (ASTRO) in Boston, MA (September 25-28, 2016).
Using a web-based application to guide follow-up for patients with advanced lung cancer after they have received initial therapy may improve survival, according to a study presented at the 2016 American Society of Clinical Oncology Annual Meeting (June 3-7; Chicago, IL).
A lack of randomized controlled trials (RCTs) shouldn’t rule out the use of effective treatment strategies, such as stereotactic ablative radiotherapy (SABR), for lung cancer, urged a prominent oncologist recently. Instead, comparative-effectiveness research should be viewed as an alternative source of evidence to determine the best treatment strategies for patients with lung cancer.
Patients with a smoking history who have lung adenocarcinoma and a targetable alteration have the same likelihood of benefitting from targeted therapy as patients without a smoking history and a targetable alteration.
A groundbreaking study demonstrated a 38% risk reduction of disease worsening or death for patients receiving an immunotherapy plus chemotherapy combination as initial treatment for advanced non-squamous NSCLC.
A novel intermediate endpoint could be a useful measure in clinical trials for metastatic non-small cell lung cancer (mNSCLC), according to a recent study published in JAMA (published online June 15, 2017; doi:10.1001/jamaoncol.2017.1029).
A recent budget analysis evaluated the costs, safety, and efficacy of personalized dosing compared with fixed dosing of standard-of-care treatment for non-small cell lung cancer, presented at the 2017 ASCO Annual Meeting (June 2-6, 2017; Chicago, IL).
A patient navigation program implemented in community health centers significantly increased lung cancer screening among underserved populations, according to research presented at the 2017 ASCO Annual Meeting (June 2-6, 2017; Chicago, IL).
A novel antibody-drug conjugate is well tolerated and induces durable responses in pretreated patients with advanced non-small cell lung cancer (NSCLC), according to research published in the Journal of Clinical Oncology (published online May 26, 2017; doi:10.1200/JCO.2016.72.1894).
The International Association for the Study of Lung Cancer (IASLC) has published its first version of the Atlas of EGFR Testing in Lung Cancer, which provides up-to-date recommendations on the testing process and interpretation of the results.